A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Public ClinicalTrials.gov record NCT01396148. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Children and young adults with gastrointestinal stromal tumors (GIST) will be treated with sunitinib. The safety (including pharmacokinetics) and tolerability of sunitinib will be studied in these patients. In addition, tumor responses and overall survival will be assessed.
Study identification
- NCT ID
- NCT01396148
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 6 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Years to 20 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2012
- Primary completion
- Jul 31, 2017
- Completion
- Jul 31, 2017
- Last update posted
- Mar 26, 2019
2012 – 2017
United States locations
- U.S. sites
- 3
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles | Los Angeles | California | 90027 | — |
| Children's Hospital Boston | Boston | Massachusetts | 02115 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
Recently updated Gastrointestinal Stromal Tumors trials
Other public records listing Gastrointestinal Stromal Tumors. Sorted by last update posted; newest first. Not a recommendation.
- NCT02012699: Integrated Cancer Repository for Cancer Research Recruiting
- NCT07171203: Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor Recruiting
- NCT05493215: Imatinib TDM in GIST Recruiting
- NCT03673501: A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib Active, not recruiting
- NCT06087263: Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. Active, not recruiting
- NCT06208748: SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01396148, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2019 · Synced Sep 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01396148 live on ClinicalTrials.gov.